Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | August 18, 2026 | August 20, 2026 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | June 08, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,438 |
Ending reported balance
After 2026-08-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-18 · Exercise / conversion · Acquired 573 · Balance 2,011 Row 2 · 2026-08-18 · Sale · Disposed 573 · Balance 1,438 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $164.30 · Expires 2027-03-02 | Direct | 0 |
Reported balance
After 2026-08-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-18 · Exercise / conversion · Disposed 573 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 3,964 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,964 |
Maze Therapeutics, Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.58 · Expires 2036-06-07 | Direct | 18,000 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 18,000 · Balance 18,000 F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 20, 2026 20:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 573 | $0.00 Strike: $164.30 | $0.00 |
DisclosureSEC source: 0001100682-26-000134 · form4.xml · derivative · entry 4 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 573 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 573 | $285.24 | $163,442.52 |
DisclosureSEC source: 0001100682-26-000134 · form4.xml · nonDerivative · entry 2 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,438 Read SEC document |
| August 18, 2026 Filed Aug 20, 2026 20:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 573 | $164.30 | $94,143.90 |
DisclosureSEC source: 0001100682-26-000134 · form4.xml · nonDerivative · entry 1 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:23 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0001804999-26-000002 · form4-06102026_080643.xml · derivative · entry 1 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2036-06-07 F1 · derivative.exercise_date: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| May 12, 2026 Filed May 14, 2026 21:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 3,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000073 · form4.xml · nonDerivative · entry 2 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 3,964 F1 · shares: Reflects the exempt transfer pursuant to Rule 16a-13 of 3,964 shares held by the reporting person to a revocable trust controlled by the reporting person. Read SEC document |
| May 12, 2026 Filed May 14, 2026 21:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 3,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000073 · form4.xml · nonDerivative · entry 1 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,438 F1 · shares: Reflects the exempt transfer pursuant to Rule 16a-13 of 3,964 shares held by the reporting person to a revocable trust controlled by the reporting person. Read SEC document |
| May 08, 2026 Filed May 11, 2026 20:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,438 | $177.62 | $255,417.56 |
DisclosureSEC source: 0001100682-26-000057 · form4.xml · nonDerivative · entry 1 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,402 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:13 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $23.67 | $0.00 |
DisclosureSEC source: 0001804999-25-000005 · form4-09242025_080904.xml · derivative · entry 1 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2035-09-21 F1 · derivative.exercise_date: The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 2,076 | $134.98 Strike: $134.98 | $280,218.48 |
DisclosureSEC source: 0001127602-25-015469 · form4.xml · derivative · entry 2 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,076 Underlying: Common Stock · 2,076 shares Expires 2035-05-21 F2 · shares: The stock options become exercisable upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 946 | $134.98 | $127,691.08 |
DisclosureSEC source: 0001127602-25-015469 · form4.xml · nonDerivative · entry 1 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,964 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 13, 2024 Filed May 15, 2024 23:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,311 | $228.41 Strike: $228.41 | $299,445.51 |
DisclosureSEC source: 0001127602-24-015536 · form4.xml · derivative · entry 2 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,311 Underlying: Common Stock · 1,311 shares Expires 2034-05-13 F2 · shares: The Stock Options become exercisable upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 13, 2024 Filed May 15, 2024 23:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 559 | $228.41 | $127,681.19 |
DisclosureSEC source: 0001127602-24-015536 · form4.xml · nonDerivative · entry 1 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,018 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/13/2025 or the business day prior to the Company's next annual meeting of shareholders Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,669 | $192.36 Strike: $192.36 | $321,048.84 |
DisclosureSEC source: 0001127602-23-015839 · form4.xml · derivative · entry 2 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,669 Underlying: Common Stock · 1,669 shares Expires 2033-05-15 F2 · shares: The Stock Options become exercisable upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 15, 2023 Filed May 17, 2023 18:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 664 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015839 · form4.xml · nonDerivative · entry 1 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,459 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/15/2024 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,582 | $222.31 Strike: $222.31 | $351,694.42 |
DisclosureSEC source: 0001127602-22-014388 · form4.xml · derivative · entry 2 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,582 Underlying: Common Stock · 1,582 shares Expires 2022-05-12 F2 · shares: The Stock Options become exercisable upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:03 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 575 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-014388 · form4.xml · nonDerivative · entry 1 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,795 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/11/2023 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,151 | $0.00 Strike: $342.55 | $0.00 |
DisclosureSEC source: 0001127602-21-016096 · form4.xml · derivative · entry 2 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151 Underlying: Common Stock · 1,151 shares Expires 2031-05-07 F2 · shares: The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 355 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016096 · form4.xml · nonDerivative · entry 1 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,220 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:33 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 2,539 | $0.00 Strike: $164.24 | $0.00 |
DisclosureSEC source: 0001127602-20-016265 · form4.xml · derivative · entry 2 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,539 Underlying: Common Stock · 2,539 shares Expires 2030-05-11 F2 · derivative.exercise_date: The Stock Options become exercisable upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:33 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 741 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-016265 · form4.xml · nonDerivative · entry 1 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 573 | $164.30 Strike: $164.30 | $94,143.90 |
DisclosureSEC source: 0001127602-20-009452 · form4.xml · derivative · entry 2 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 573 Underlying: Common Stock · 573 shares Expires 2027-03-02 F2 · derivative.exercise_date: Options become exercisable one year from the date of grant. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 124 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-009452 · form4.xml · nonDerivative · entry 1 Andrews Nancy C · CIK 0001804999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124 F1 · kind: Consists of 124 unvested restricted stock units that vest on 3/02/2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.